This product does NOT contain THC, and thus does not have a psychoactive component.
Clinically Effective for:
- Seizure disorder (epilepsy)
A specific cannabidiol product (Epidiolex, GW Pharmaceuticals) has been shown to reduce seizures in adults and children with various conditions that are linked with seizures. This product is a prescription drug for treating seizures caused by Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex. It has also been shown to reduce seizures in people with Sturge-Weber syndrome, febrile infection-related epilepsy syndrome (FIRES), and specific genetic disorders that cause epileptic encephalopathy. But it’s not approved for treating these other types of seizures. This product is usually taken in combination with conventional anti-seizure medicines. Some cannabidiol products that are made in a lab are also being studied for epilepsy. But research is limited, and none of these products are approved as prescription drugs.
Possibly Effective for:
- Multiple sclerosis (MS)
A prescription-only nasal spray product (Sativex, GW Pharmaceuticals) containing both 9-delta-tetrahydrocannabinol (THC) and cannabidiol has been shown to be effective for improving pain, muscle-tightness, and urination frequency in people with MS. This product is used in over 25 countries outside of the United States. But there is inconsistent evidence on the effectiveness of cannabidiol for symptoms of multiple sclerosis when it is used alone. Some early research suggests that using a cannabidiol spray under the tongue might improve pain and muscle tightness, but not muscle spasms, tiredness, bladder control, mobility, or well-being and quality of life in patients with MS.
- Crohn’s disease
Early research shows that taking cannabidiol does can reduce disease activity in adults with Crohn disease.
Early research shows that taking cannabidiol may improve blood glucose control adults with type 2 diabetes.
There is evidence to suggest that CBD is beneficial for dystonia, a movement disorder marked by involuntary muscle contractions.
- Fragile-X syndrome
Early research suggests that applying cannabidiol gel might reduce anxiety and improve behavior in children with fragile X syndrome, an inherited condition marked by learning disabilities.
- Graft-versus-host disease
GVHD is a complication that can occur after a bone marrow transplant, where the transplant attacks the body . Early research has found that taking cannabidiol daily starting 7 days before bone marrow transplant and continuing for 30 days after transplant can extend the time it takes for a person to develop GVHD.
- Huntington’s disease
Early research shows that taking cannabidiol daily may improve symptoms of Huntington disease, an inherited brain disorder that affects movements, emotions, and thinking.
- Withdrawal from heroin, morphine, and other opioid drugs
Early research shows that taking cannabidiol for 30 days might reduce cravings and anxiety in people with heroin use disorder.
- Parkinson’s disease
Early research shows that cannabidiol might reduce anxiety and psychotic symptoms in people with Parkinson’s disease.
Early research suggests that taking cannabidiol improves symptoms and well-being in people with schizophrenia.
- Quitting smoking
Early research suggests that inhaling cannabidiol with an inhaler for one week might reduce the number of cigarettes smoked by smokers trying to quit.
- Social Anxiety Disorder
Early research shows that cannabidiol might improve anxiety in people with this disorder, but it’s unclear if it helps reduce anxiety during public speaking.
- Temporomandibular joint disorders
A group of painful conditions that affect the jaw joint and muscle (TMD). Early research shows that applying a liquid containing cannabidiol to the skin might reduce pain in people with TMD.
- Peripheral neuropathy
Nerve damage in the hands and feet.
- Bipolar disorder